MARKET

BDX

BDX

Becton Dickinson & Co
NYSE

Real-time Quotes | Nasdaq Last Sale

252.30
+1.16
+0.46%
After Hours: 252.30 0 0.00% 16:28 05/20 EDT
OPEN
252.40
PREV CLOSE
251.14
HIGH
253.47
LOW
247.82
VOLUME
910.92K
TURNOVER
0
52 WEEK HIGH
280.62
52 WEEK LOW
229.24
MARKET CAP
71.92B
P/E (TTM)
39.78
1D
5D
1M
3M
1Y
5Y
BD (BDX) Introduces New Molecular Diagnostic Platform in US
BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
Zacks · 2d ago
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
Zacks · 4d ago
Why Embecta Shares Are Falling Today
Benzinga · 05/13 13:06
BRIEF-BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform In The U.S.
reuters.com · 05/12 11:01
BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.
PR Newswire · 05/12 10:50
BRIEF-Babson, BD Expand Strategic Partnership To Advance Diagnostic Blood Collection In New Care Settings
reuters.com · 05/11 10:51
Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings
Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection i...
PR Newswire · 05/11 10:50
Insider Sell: Becton Dickinson
MT Newswires · 05/10 15:30
More
No Data
Learn about the latest financial forecast of BDX. Analyze the recent business situations of Becton Dickinson & Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
22.22%Buy
55.56%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BDX stock price target is 283.67 with a high estimate of 310.00 and a low estimate of 255.00.
High310.00
Average283.67
Low255.00
Current 252.30
EPS
Actual
Estimate
0.911.822.733.64
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 2.07K
Institutional Holdings: 275.74M
% Owned: 96.73%
Shares Outstanding: 285.06M
TypeInstitutionsShares
Increased
576
15.17M
New
195
2.85M
Decreased
506
13.59M
Sold Out
85
753.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.35%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Chairman/President/Chief Executive Officer/Chief Operating Officer/Director
Thomas Polen
Chief Financial Officer/Executive Vice President
Christopher DelOrefice
Corporate Executive
David Hickey
Chief Human Resource Officer/Executive Vice President
Betty Larson
Executive Vice President/Chief Administrative Officer
Christopher Reidy
Executive Vice President/Chief Marketing Officer
Antoine Ezell
Executive Vice President/General Counsel
Samrat Khichi
Executive Vice President
Simon Campion
Executive Vice President
Alexandre Conroy
Executive Vice President
Roland Goette
Executive Vice President
James Lim
Executive Vice President
Alberto Mas
Senior Vice President/Chief Accounting Officer/Controller
Thomas Spoerel
Lead Director/Independent Director
Marshall Larsen
Independent Director
William Brown
Independent Director
Catherine Burzik
Independent Director
Carrie Byington
Independent Director
R. Andrew Eckert
Independent Director
Claire Fraser
Independent Director
Jeffrey Henderson
Independent Director
Christopher Jones
Independent Director
Timothy Ring
Independent Director
Bertram Scott
No Data
No Data
About BDX
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Webull offers kinds of Becton Dickinson and Co stock information, including NYSE:BDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDX stock methods without spending real money on the virtual paper trading platform.